US FDA Rare Pediatric Disease Designation in Rett syndrome
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The FDA's recognition highlights the serious nature of Rett syndrome and the need for innovative treatments in this area. Neurotech's CEO emphasized the significance of this milestone for the company's commitment to developing therapies for pediatric neurological disorders.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurotech International Ltd. on 6ix
Story so far
Earlier from Neurotech International
- Appendix 4E & Annual Report to shareholders
- Positive Human PK Study Results for NTI164
- NTI164 Preclinical Toxicology Studies Update
- Appendix 4D and Half Year Accounts
- Positive Opinion on OMPD for NTI164 in Europe
Later from Neurotech International
- Neurotech receives $4.73m R&D Tax Incentive Refund
- Trading Halt
- Binding Commitments Received for a $4 Million Placement
- Quarterly Activities/Appendix 4C Cash Flow Report
- Approval received for NTI164 Phase 3 Clinical Study in ASD
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International